At that point, assuming we like the way its coming together, we negotiate a pre-defined exit path for a possible investment: upon successful completion of XYZ clinical study, the Pharma will buyout the asset-centric entity in an upfront plus milestones type transaction.

FORBES: New Biotech Corporate Structures: Possible Alternatives For Discovery Platforms and Product Financings

Exit polls showed nearly two-thirds of all voters favor a path to legal status.

FORBES: Bipartisanship Needed On Skilled Immigration Reform